Alexion Pharmaceuticals, Boston

alexion.com

121 Seaport Blvd.

Boston, MA 02210

Company Info

Phone
(475) 230-2596

Year Established
1992

Ticker
AZN

Exchange
NASDAQ

Contacts

Marc Dunoyer
CEO

Sean Christie
CFO & CAO

Todd Spalding
General Counsel

Fred Chereau
Senior VP, Strategy & Business Development

Scott Weintraub
Senior VP, U.S. Commercial Operations

Ruth Diazaraque
VP, R&D

Company Description

Alexion, an AstraZeneca company, has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).